FormWeb • delafloxacin

Delafloxacin was reviewed by the System Antimicrobial Stewardship Committee in January 2019. The decision was made to NOT add delafloxacin (Baxdela) to the Houston Methodist Formulary at this time.

For additional information:

Houston Methodist Antimicrobial Stewardship page

Black Box Warnings: Tendinitis, tendon rupture; Pediatric Use

Last updated: Aug. 2, 2024

Black Box Warnings: Serious Adverse Reactions Including Tendinitis, Tendon Rupture, Peripheral Neuropathy, Cental Nervous System Effects, and Exacerbation of Myasthenia Gravis

This site is intended for the staff of Houston Methodist.
While others may view accessible pages, Houston Methodist makes no warranty, express or implied,
as to the use of this information outside of Houston Methodist.